好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Dual Antiplatelet Therapy Versus Tissue Plasminogen Activating Factor with Acute Minor Ischemic Stroke: A Systematic Review and Meta-analysis of Safety and Efficacy
Cerebrovascular Disease and Interventional Neurology
S41 - Sociodemographics of Stroke and Policy in Stroke Care (1:24 PM-1:36 PM)
003
To assess the safety and efficacy of DAPT versus t-PA in acute minor ischemic stroke.
Acute minor ischemic stroke is a common and challenging clinical scenario that requires prompt intervention to optimize patient outcomes. Two primary treatment options have emerged in recent years: Dual Antiplatelet Therapy (DAPT) and tissue plasminogen activating factor (t-PA). 
Following Cochrane and PRISMA guidelines, we analyzed observational studies and clinical trials comparing DAPT and t-PA in this patient group. Databases included PubMed, Scopus, and Web of Science. Data extraction included study characteristics, patient demographics, and analyzed outcomes. RevMan 5.3 analyzed data and OpenMetaAnalyst 2021 assessed heterogeneity, while the risk of bias was determined with RoB 2.0 and the Newcastle-Ottawa scale.

In a meta-analysis of 5 studies involving 3,978 DAPT-treated and 2,224 t-PA-treated patients, we found no significant differences between DAPT and t-PA groups for Modified Rankin Scale (mRs) scores of 0-1 OR 1.11 (95% CI: 0.79, 1.55, p = 0.56), mRs scores of 0-2 OR 0.90 (95% CI: 0.61, 1.31, p = 0.57), and combined mRs scores OR 1.05 (95% CI: 0.82, 1.34, p = 0.72). There were also no significant disparities in NIHSS change from baseline MD 0.32 (95% CI: -0.35, 0.98, p = 0.35) and mortality rates OR 0.87 (95% CI: 0.26, 2.93, p = 0.83) between the two treatment groups. However, the analysis revealed a significantly lower incidence of symptomatic intracranial hemorrhage (sICH) in the DAPT group OR 0.10 (95% CI: 0.04, 0.26, p < 0.00001) and a significantly lower incidence of any bleeding OR 0.31 (95% CI: 0.14, 0.69, p = 0.004) when compared to the t-PA group.
Our meta-analysis found no significant differences in efficacy outcomes between DAPT and t-PA. However, DAPT demonstrated a significantly lower risk of sICH and bleeding compared to t-PA.
Authors/Disclosures
Mostafa M. Meshref, MD (Al-Azhar University, Cairo)
PRESENTER 		Dr. Meshref has nothing to disclose.
Abdallah Abbas Dr. Abbas has nothing to disclose.
Abdullah Ashraf Hamad (Menoufia University) Dr. Hamad has nothing to disclose.
Mostafa El Din Moawad Mostafa El Din Moawad has nothing to disclose.
Dalia Kamal Ewis No disclosure on file
Rana Ahmed Youssef No disclosure on file
Heba Hamouda No disclosure on file
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College) Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .